Peter C. Everett MD
Assistant Professor, Hematology & Medical Oncology
818 Harrison Ave | (617) 638-7526peter.everett@bmc.org
peverett@bu.edu

Sections
Hematology & Medical Oncology
Centers
Evans Center for Interdisciplinary Biomedical Research
Biography
Dr. Peter Everett is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the Section of Hematology and Medical Oncology at Boston Medical Center (BMC). He received his undergraduate degree from Cornell University and his medical degree from Chobanian and Avedisian School of Medicine. Following that, he completed training in Internal Medicine and a fellowship in Hematology and Medical Oncology at Boston Medical Center, where he also served as the Chief Fellow. Dr. Everett specializes in head, neck and thoracic oncology.
Websites
Education
Medicine-Internal, MD, Boston University School of Medicine
Applied Physics, BS, Cornell University
Publications
Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2024 Nov 27. PMID: 39603266.
Published on 6/8/2023Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.
Published on 8/1/2022Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893. PMID: 36071763.
Published on 10/19/2021Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478. PMID: 34667025.
Published on 8/3/2021Freydman J, Henshaw L, Patel JV, Smith CE, Everett PC. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. Ann Pharmacother. 2022 04; 56(4):503-504. PMID: 34344199.
Published on 10/20/2020Tapan U, Furtado VF, Qureshi MM, Everett P, Suzuki K, Mak KS. Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC. JTO Clin Res Rep. 2021 Jan; 2(1):100109. PMID: 34589974.
Published on 1/9/2019Shah NK, Qureshi MM, Dyer MA, Patel SA, Kim K, Everett PC, Grillone GA, Jalisi SM, Truong MT. Optimal sequencing of chemoradiotherapy for locally advanced laryngeal cancer. Laryngoscope. 2019 10; 129(10):2313-2320. PMID: 30628077.
Published on 2/8/2018Kirke DN, Qureshi MM, Kamran SC, Ezzat W, Jalisi S, Salama A, Everett PC, Truong MT. Role of adjuvant chemoradiotherapy in T4N0 stage IV head and neck cancer: A National Cancer Database analysis. Head Neck. 2018 06; 40(6):1174-1184. PMID: 29417687.
Published on 4/25/2012Tan JN, Kroll MH, O'Hara CJ, Everett PC, Erdogan E. Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement. Clin Chim Acta. 2012 Oct 9; 413(19-20):1696-9. PMID: 22561184.
Published on 9/2/2010Ren JG, Seth P, Everett P, Clish CB, Sukhatme VP. Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One. 2010 Sep 02; 5(9). PMID: 20824065.